Search

Your search keyword '"Weiss, Brian"' showing total 806 results

Search Constraints

Start Over You searched for: Author "Weiss, Brian" Remove constraint Author: "Weiss, Brian"
806 results on '"Weiss, Brian"'

Search Results

1. Lipid metabolism dysfunction following symbiont elimination is linked to altered Kennedy pathway homeostasis

3. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.

4. Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

5. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

6. Infection with endosymbiotic Spiroplasma disrupts tsetse (Glossina fuscipes fuscipes) metabolic and reproductive homeostasis.

8. Comparative genomic analysis of six Glossina genomes, vectors of African trypanosomes

10. The Glossina Genome Cluster: Comparative Genomic Analysis of the Vectors of African Trypanosomes

11. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

12. Symbiotic microbes affect the expression of male reproductive genes in Glossina m. morsitans.

14. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis

15. A fine-tuned vector-parasite dialogue in tsetse's cardia determines peritrophic matrix integrity and trypanosome transmission success.

17. Molecular characterization of tsetse's proboscis and its response to Trypanosoma congolense infection.

21. Unravelling the relationship between the tsetse fly and its obligate symbiont Wigglesworthia: transcriptomic and metabolomic landscapes reveal highly integrated physiological networks

22. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine

23. Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1.

24. Grandeur Alliances: Symbiont Metabolic Integration and Obligate Arthropod Hematophagy.

25. Gadolinium‐based contrast media does not improve the staging of neuroblastoma image‐defined risk factors at diagnosis

26. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

27. Vitamin B6 Generated by Obligate Symbionts Is Critical for Maintaining Proline Homeostasis and Fecundity in Tsetse Flies

28. Trypanosome transmission dynamics in tsetse

36. Long-Term Safety and Efficacy of Selumetinib in Children with Neurofibromatosis Type 1 on a Phase 1/2 Trial for Inoperable Plexiform Neurofibromas

38. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

42. Supplemental Figure 1 from Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

43. Data from Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

44. Figure A1 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

45. Supplemental Figure 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

46. Supplemental Table 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

47. Supplementary Figure Legends from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

48. Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

49. Supplemental Table 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

50. Supplemental Patients, Methods, and Tables from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

Catalog

Books, media, physical & digital resources